In this e-book, Lonza experts review important aspects of developing and manufacturing bispecific antibodies (bsAbs), with editorial highlights from the past year. Read on to discover the impact that poor assembly and expression can have on downstream purification and formulation, and how addressing these challenges at an early stage, using specialized strategies and technologies, ensures cost-effective production of high quality bsAb-based drug candidates to tight timelines.

Lisa Prendergast, PhD, Associate Director, Expression System Sciences in Licensing
Rebecca Michael, PhD, Principal Group Leader, Cell and Molecular Biology Group
Karl Rogerson, MSc, Senior Principal Scientist, Global Process and Analytical Development Sciences

By clicking "Access Content" you agree to our Legal Disclaimer and the Lonza Privacy and Cookies Policy.

Latest content

Latest briefing from the Knowledge Center